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an overwhelming consensus that low doses have largely eliminated 
pulmonary toxicity as a reason to withdraw amiodarone therapy in 
the first place. As Magro et al. (2) put it, “ to withhold or 
withdraw potentially lifesaving therapy from patients frequently 
resistant to all other available antiarrhythmic medications based on 
preexisting abnormalities or a reduction in pulmonary function alone 
does not appear to be justified in the case of amiodarone.” 
In the use of amiodarone one has to remember that “poison is in 
everything, and no thing is without a poison. The dosage makes it 
either a poison or a remedy” (23). 
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Reply 
I agree with Kerin and Rubenfire that the incidence of pulmonary 
toxicity caused by amiodarone is reduced when the loading and 
maintenance doses of amiodarone are lowered. I appreciate their 
agreement that routine serial pulmonary function studies are not 
indicated in the follow-up of patients receiving amiodarone therapy. 
LEONARD N. HOROWITZ. MD. FACC 
Presbyterian Medical Center 
39th and Marker Streets 
Philadelphia, Pennsylvania 19104 
Dilated Cardiomyopathy 
Dystrophy 
in Myotonic 
Nguyen et al. (1) noted that 6 of their 12 autopsy cases of myotonic 
dystrophy had cardiac enlargement that was consistent with dilated 
cardiomyopathy in 3 cases. They cite other authors who have 
observed clinically undiagnosed cardiomegaly in autopsy cases. 
Perloff et al. (2) did not find echocardiographic evidence of ventric- 
ular dysfunction in their patients. We report a patient with the 
uncommon association of myotonic dystrophy and dilated cardio- 
myopathy with clinically overt congestive heart failure in the 
absence of an underlying chronic rhythm disturbance. 
A 42 year old white man with a history of progressive “hand 
stiffness” since adolescence presented to his family doctor with a 2 
year history of increasing shortness of breath and was found to be in 
congestive heart failure. He was transferred to our center for cardiac 
evaluation. On physical examination there was a paucity of cardio- 
vascular findings. The heart tones were distant; there was no atria1 
or ventricular gallop, murmur or increased jugular venous pressure. 
Chest radiographs showed massive cardiomegaly and mild pulmo- 
nary vascular congestion. The electrocardiogram showed normal 
sinus rhythm with left bundle branch block and a slightly prolonged 
PR interval (0.21 s). 
M-mode and two-dimensional echocardiography demonstrated a 
dilated, poorly contracting left ventricle with markedly diminished 
left ventricular ejection fraction (~10%). At cardiac catheterization, 
the right heart pressures were normal (right ventricle 20112 and 
pulmonary artery 2011.5 mm Hg, mean 18). The pulmonary capillary 
wedge pressure was 14 mm Hg and left ventricular pressure 90115 
mm Hg. There was mild systemic hypotension (aorta 90170 mm Hg). 
Thermodilution cardiac output was markedly diminished (1.32 liters/ 
min). Pulmonary vascular resistance was not elevated, but systemic 
vascular resistance was elevated (4.12 dynes/slcmm5). Left ventric- 
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ulography showed a massive severely hypokinetic left ventricle 
without mitral regurgitation. The ejection fraction was markedly 
depressed. Coronary angiography was normal. The patient refused 
the option of cardiac transplantation and remains on medical therapy. 
The diagnosis of myotonic, dystrophy was based on the myoto- 
nia, mildly diminished intellect and classic expressionless facies of 
the patient with frontal baldness (onset in the 3rd decade of life), 
mild ptosis and wasting of the facial musculature. The family history 
was remarkable for six similarly affected males in four generations. 
The brother of the patient had had myotonia and similar facial 
appearance: his death at age 26 was reported to be due to congestive 
heart failure, attributed to childhood rheumatic fever, but the 
possibility of cardiomyopathy related to myotonic dystrophy cannot 
be ruled out. 
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related variables is accounted for in a multivariate regression model, 
the statistical impact of the second usually markedly diminishes. 
Was left ventricular ejection fraction at rest a significant univariate 
predictor of death and myocardial infarction at the first step of the 
model that excluded coronary revascularization as an event? If, on 
the basis of the results of previous studies, left ventricular ejection 
fraction at rest is “forced” in at the first step in the Cox model, is the 
strong association of exercise lung/heart thallium uptake and out- 
come maintained’? 
3. If death is considered as the only end point, how do left 
ventricular ejection fraction at rest and exercise lung/heart ratio 
compare on a univariate basis? 
In summary, previous work has shown that left ventricular 
ejection fraction at rest is strongly related to prognosis in coronary 
artery disease. The current study suggests it should be abandoned 
completely as a prognostic factor. We believe that further critical 
examination of the data in the current study is warranted to clarify 
this difference. 
CHARLES P. TALIERCIO, MD, FACC 
RAYMOND J. GIBBONS, MD, FACC 
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We are concerned about several aspects of the recent report by Kaul 
et al. (I). In this follow-up study of 204 patients, the quantitatively 
assessed exercise lung/heart ratio of thallium activity was found to 
be the most important predictor of future cardiac events (death, 
myocardial infarction or coronary bypass surgery). When compared 
with other clinical variables by a Cox model, left ventricular ejection 
fraction at rest was not a predictor of future cardiac events in the 
initial Cox model, a model in which lung/heart thallium ratio was 
omitted or a model in which coronary revascularization was ex- 
cluded as an event. These findings are surprising in view of (I) the 
data in Tables 3 and 4, which show a mean ejection fraction at rest 
of 63% in patients followed up without an event compared with 43% 
in those who died on follow-up; and (2) multiple previous studies (2- 
6) that have documented the strong association of left ventricular 
function at rest and prognosis. We would appreciate it if the authors 
would respond to three concerns: 
I. Was the angiographic measurement of left ventricular ejection 
fraction at rest in this study accurate in the entire cohort of patients‘? 
Were poor quality ventriculograms or ventriculograms with prema- 
ture ventricular contractions analyzed? Was an ejection fraction 
obtained in all patients’? 
2. Do left ventricular ejection fraction at rest and lung/heart 
thallium uptake contain overlapping information that was obscured 
by the multivariate analysis? Once the first of two competing, 
4. Hammermei\ter KE. DeRouen TA, Dodge HT. Variables predictive of survival in 
patients with coronary disease: selection by univariate and multivariate analyses from 
the clinical. electrocardiographic. exercise. arteriographic and quantitative angiographic 
evaluations. Circulation 1979:59:4?1-30. 
5. Weiner DA. Ryan TJ. McCabe CH. et al. Prognostic importance ofa clinical profile and 
exercise test in medically treated patients with coronary artery direare. J Am Coil 
Cardiol 1984.3:77!-9. 
6. Taliercio CP. Clement!, IP, Zinsmeirter AR, Gibbons RJ. Prognostic value and 
hmltation\ of exercise radionuclide anglography m medically treated coronary artery 
disease. Mavo Clm Proc 1988;63:573-81. 
Repb 
Taliercio and Gibbons have obviously “overreacted” to the results 
of our study. In their last paragraph they state that “the current 
study suggests that it [left ventricular ejection fraction] should be 
abandoned completely as a prognostic factor.” We have neither said 
nor implied this anywhere in our study. All we stated in our article 
is that if patients with chest pain have both catheterization and 
thallium-201 data available, then the quantitatively analyzed lung/ 
heart ratio of thallium-201 is a better prognostic indicator than is any 
catheterization-derived variable. (I) In another study from the 
University of Virginia (2), the number of diseased vessels was also 
the only catheterization-derived variable that predicted future 
events. We are aware of the recent report of Taliercio et al. (3) 
